Micron Technology [MU]
Investing Hub Research | July 27, 2026 | Task 6 of 9
Prerequisite: Tasks 1–5 complete. Migrated to the Criteria framework 2026-07-29. Every trigger below is tied to a named Criteria from the analysis document, because the only reason to track these is that they change a Criteria score. No position verdict is expressed here or anywhere else in this memo — the prior version described these as triggers that "change the Watchlist decision"; there is no Watchlist decision.
Date sourcing note: Micron's fiscal year ends in late August/early September, and it has historically reported FQ4 in late September and FQ1 in mid-to-late December. Exact dates are not yet confirmed by the company's IR calendar and are marked as estimated windows — verify against IR before acting on any dated trade.
| Date / window | Catalyst | Linked to | Upgrade trigger (toward Long) | Downgrade trigger (toward Short) |
|---|---|---|---|---|
| Monthly, ongoing | FY2027 consensus EPS revision counts (Alpha Vantage EARNINGS_ESTIMATES) |
Quality Criteria + Momentum Criteria — the cheapest, fastest signal available | Revisions stay net positive and FY27 EPS holds above ~$150 | E1: trailing-30-day revisions turn net negative (from 30↑/0↓ today). This is the highest-value single thing to watch |
| Monthly, ongoing | DRAM contract and spot pricing | Quality Criteria (mechanism evidence) | Contract pricing flat-to-up; HBM allocations extended into 2028 | E3: two consecutive monthly declines in contract pricing |
| ~Late Sept 2026 (est.) | FY2026 Q4 earnings + first formal FY2027 framing | Catalyst Criteria — the primary catalyst. Directly tests the −22%/−42% FY2027 variant | FY27 revenue guided at/above ~$239B (consensus) with margin held above 80% | E2: FY27 revenue guided below ~$185B (house Base), or the first sequential gross-margin decline |
| Ongoing, no fixed date | CXMT post-IPO capacity milestones; competitor (Samsung/SK Hynix) capex announcements | Quality Criteria | Incumbents hold capital discipline; CXMT capacity proves conventional-DRAM only and cannot address HBM | Volume-production milestones on HBM-capable capacity, or an industry capex escalation |
| Ongoing, policy-driven | US HBM export restriction decisions | Quality Criteria (Risk #5) | Restrictions shelved, or scoped so narrowly that Micron's addressable demand is unaffected | Restrictions enacted that materially reduce addressable HBM demand |
| ~Mid/late Dec 2026 (est.) | FY2027 Q1 earnings | Quality Criteria + Catalyst Criteria confirmation | Second consecutive quarter validating the FY27 guide | A guide-down, or margin rolling over sequentially |
| Continuous (price) | 200-day moving average, currently ~$505 and rising | Momentum Criteria — the tape trigger | Price reclaims the 50-day (~$957) and makes a new high above $1,213.37 → bearish tape thesis invalidated | T1: weekly close below the 200-day MA, or T2: weekly lower-high/lower-low with a 50/200 bear cross |
This is not a conversion rule for a position — no position verdict exists. It is the standard of evidence a book should require before treating the impairment case as live: one expectations trigger AND one tape trigger, not either alone. The tape trigger is a Momentum Criteria observation and governs timing only; it can never by itself make or unmake the case for owning the name.
It becomes an actionable Long only near ~$475 with the HBM contract structure demonstrably intact, or on disclosure of a second contracted year at post-peak margins with industry capacity discipline holding.
A weekly close above the prior high of $1,213.37, or reported sequential gross-margin expansion above 85% paired with FY2028 revenue guidance above $250B. Either would mean the regime-change case is winning on evidence, and the memo's whole mean-reversion anchor would need to be rebuilt rather than defended.
Per the skill, ongoing monitoring of this calendar hands off to the plugin skills
equity-research:catalyst-calendar (maintaining dates across the coverage list) and
equity-research:thesis-tracker ("is the thesis still intact" checks as data arrives). Do not re-run a full
initiation when a trigger fires — use the investment-memo skill's Task 8 incremental refresh, which will
also run the required PEAD check against the new print.
The highest-value, lowest-cost monitoring action is the monthly Alpha Vantage revision pull: one API call tells you whether E1 has fired, and E1 is the trigger most likely to fire first.
The mention-frequency run surfaced an emerging term with no dated event attached, which per the methodology is a catalyst to go find. It produced the single cleanest checkable trigger this name has ever had.
| # | Date | Event | Why it matters | Upgrade / downgrade threshold |
|---|---|---|---|---|
| C-A | ~late Sept 2026 (FY26 Q4 print) | First full RPO disclosure in a 10-K | Micron began disclosing remaining performance obligations for the first time in the May 2026 quarter: $5B at FQ3, "approximately $100B" including SCAs executed after quarter end. The FY2026 10-K is the first filing in which the ~$100B claim becomes an audited, contractual line item rather than a call statement | Downgrade if reported RPO fails to converge toward ~$100B, or if the disclosed figure is materially below the claim. Upgrade if it converges and grows |
| C-B | Each quarter, ongoing | SCA count and coverage progression | Management targets "approximately half or more of company revenue" under SCAs. 16 signed to date | Downgrade if the count stalls, or if any signed SCA is disclosed as amended, renegotiated or impaired — take-or-pay contracts are only worth their counterparties' solvency |
| C-C | Each quarter, ongoing | CDBU/MCBU vs CMBU gross-margin divergence | The v1.4.0 segment work found conventional-DRAM units now out-earn the HBM unit (87% vs 83%). Because commodity pricing is the mean-reverting variable, this specific divergence — not aggregate margin — is the earliest read on the cycle turning underneath the contracts | Downgrade on CDBU/MCBU rolling over while CMBU holds. Upgrade if CDBU/MCBU hold above 80% for two more quarters |
| C-D | End-CY2026 | CXMT HBM3 production milestone | Independent research puts CXMT at ~350k wafer starts/month by end-2026 but competitive-yield HBM volume at 2028+. Its capacity lands on conventional DRAM — now Micron's highest-margin business | Downgrade if CXMT announces qualified HBM3 volume shipment earlier than expected, or DDR5 share gains accelerate outside China |
C-A did not exist as a checkable trigger before this revision. It is the highest-value output of the unpublished-scoping pass for monitoring purposes: a contractual claim that becomes falsifiable in a single audited line item, on a known date.